Skip to content
Speak with our advisory team

25 Oct 2026 · TAMA Insight

Indonesia’s Proposed CPOB Changes for Plasma-Derived Medicinal Products: Scope, Safety and Compliance

Indonesia’s Food and Drug Authority (Badan Pengawas Obat dan Makanan or “BPOM”) is proposing changes to Good Manufacturing Practice requirements for plasma-derived medicinal products (Produk Obat Derivat Plasma…

Indonesia’s Proposed CPOB Changes for Plasma-Derived Medicinal Products Scope, Safety and Compliance

Indonesia’s Food and Drug Authority (Badan Pengawas Obat dan Makanan or “BPOM”) is proposing changes to Good Manufacturing Practice requirements for plasma-derived medicinal products (Produk Obat Derivat Plasma or “PODP”). The proposal addresses the facilities covered by the framework, plasma sourcing and contract fractionation, traceability, viral safety, and documentation supporting the manufacture of these products.

The proposed changes would amend BPOM Regulation No. 7 of 2024 on Good Manufacturing Practice Standards, as amended by BPOM Regulation No. 7 of 2025 (“CPOB Regulation”). BPOM’s regulatory monitoring materials identify the revision of the blood and plasma manufacturing annex as a draft under public consultation. This article discusses the consultation proposal separately from existing requirements; adoption of a final amendment has not been verified for this review.

For pharmaceutical manufacturers, plasma fractionation facilities, blood management units, plasma banks, and businesses using human plasma derivatives, the proposal warrants a review of responsibilities across the supply chain. Several safeguards discussed in the proposal already appear in the existing CPOB standards, so assessing its impact requires distinguishing continuing obligations from proposed additions and refinements.

1. What Is the Existing Regulatory Framework for Plasma-Derived Medicinal Products?

Government Regulation No. 28 of 2024 on the Implementation of Law No. 17 of 2023 on Health (“Government Regulation 28/2024”) provides the broader framework for plasma collection, management, and fractionation. Plasma fractionation separates plasma into protein fractions used to manufacture PODP. The framework requires plasma for fractionation to come from plasma banks or blood management units that meet CPOB standards, while the resulting medicinal products must satisfy safety, efficacy, and quality requirements and obtain the applicable BPOM marketing authorisation.

The CPOB Regulation supplies the general manufacturing standards and the existing annex governing products derived from human blood or plasma. Its requirements operate alongside those applicable to particular manufacturing activities, including sterile production, biological products, quality control, documentation, and outsourced activities.

BPOM Regulation No. 11 of 2025 on Good Manufacturing Practice Standards in Blood Management Units and Plasma Banks (“BPOM Regulation 11/2025”) addresses the earlier stages of the supply chain. It covers donor selection, collection, testing, processing, storage, and distribution of blood or plasma within its scope. These activities therefore already operate under a dedicated quality framework.

Certification is addressed separately under BPOM Regulation No. 16 of 2026 on Certification of Good Manufacturing Practice and Good Distribution Practice (“BPOM Regulation 16/2026”), promulgated on 29 September 2026. Businesses should distinguish the standards governing their operations, the certification applicable to their facilities, and the marketing authorisation required for their products.

2. Proposed Expansion of Facility Coverage and a More Specific PODP Annex

The consultation draft would expressly include other production facilities recognised under applicable legislation among the entities required to use CPOB standards. This would broaden the wording beyond pharmaceutical industries and the specified categories of manufacturing institutions.

The practical scope of that addition would depend on the activities performed and the facility’s regulatory classification. Businesses should examine which entity collects plasma, conducts testing, performs fractionation, manufactures intermediates, or releases finished products. The proposed wording should not be treated as automatically imposing an identical certification obligation on every participant in the supply chain.

The draft would also rename and revise the relevant manufacturing annex to focus expressly on PODP and their starting materials, including plasma used for domestic fractionation and imported products or materials within its scope. General CPOB chapters and other relevant annexes would continue to apply unless otherwise specified.

Blood components used for transfusion would remain outside the annex’s stated scope. However, this exclusion already appears in the existing CPOB annex. The proposal therefore refines the presentation and treatment of PODP rather than introducing that distinction for the first time.

3. Contract Fractionation and Cross-Border Plasma Supply

The proposed annex expressly addresses starting materials imported or exported for contract fractionation. For imported plasma used in those arrangements, it refers to compliance with national quality and safety requirements or equivalent requirements for blood components. Activities performed in Indonesia would remain subject to the applicable CPOB standards.

These manufacturing requirements must be considered alongside the separate rules governing the movement of plasma and medicinal products across borders. Compliance with CPOB does not, by itself, establish permission to import or export a particular material or product.

The draft also places emphasis on written arrangements between plasma suppliers and fractionation facilities or manufacturers. Those arrangements would address responsibilities, quality systems, documentation, donor selection and testing, storage, transport, and communication of information discovered after donation.

For businesses negotiating contract fractionation arrangements, the practical priority is to make quality responsibilities operational. Contracts should identify who supplies records, investigates deviations, communicates safety information, and coordinates action where a donation may affect multiple pools or finished-product batches. Audit rights and access to supporting information should match those responsibilities.

4. Traceability and Look-Back Procedures Across the Plasma Supply Chain

Traceability connects individual donations to plasma pools, manufacturing activities, and finished-product batches. It also enables investigation in the reverse direction when a concern arises about a product already manufactured or distributed.

The proposal describes responsibilities across blood management units, plasma banks, fractionation facilities, subsequent manufacturers, and marketing authorisation holders. Its practical focus is on maintaining continuity when materials and information pass between different organisations.

Look-back procedures support this system when information discovered after donation raises a safety concern. Relevant circumstances include a donor subsequently testing positive for a viral marker, a failure to follow an approved testing procedure, or information suggesting that an infection may be linked to a donation.

The six-month period requires careful treatment. The existing CPOB annex already states that look-back should cover previous donations for at least six months before the last negative donation. It should therefore not be presented as a new period created by the proposed amendment.

For affected businesses, the compliance question is whether records and communication arrangements can support an effective investigation. Donor information, donation identifiers, pooling records, and batch documentation need to remain sufficiently connected to identify affected materials and support decisions on their disposition.

5. Inventory Holding Time as a Risk-Based Safety Measure

The consultation draft expressly links inventory holding time to the assessment of infectious-agent risks. It contemplates an internal quarantine period before plasma processing, allowing plasma identified as unsuitable through look-back investigations to be excluded.

The draft does not establish a single numerical holding period applicable to every operation. The proposed approach relies on risk assessment, including the characteristics of the manufacturing process, the size of the plasma pool, testing arrangements, and viral reduction measures.

This has implications for both quality management and production planning. Facilities should assess how their inventory controls identify quarantined material, prevent premature processing, and respond to safety information received after collection.

Any operational review should involve quality personnel alongside procurement and production teams. A holding period has limited value unless the organisation can receive relevant information, identify the affected plasma, and prevent its release into processing when required.

6. Viral Safety and Separation of Processing Stages

The proposed annex addresses the separation of processing stages before and after viral inactivation. It envisages dedicated and separate facilities and equipment to reduce the risk of contamination between treated and untreated materials.

Existing CPOB standards already address this risk and contemplate dedicated premises and equipment for processed products. The proposed wording develops that approach by expressly referring to processing stages on both sides of viral inactivation.

For fractionation facilities, the practical review should cover the movement of materials, equipment, and personnel, together with cleaning arrangements and the identification of treated and untreated intermediates. The required controls should be assessed against the actual process and the applicable standards.

Viral inactivation and removal also depend on validated procedures. Deviations affecting these processes require investigation and an assessment of their implications for product safety. Facility separation is one element of a wider control strategy that also includes plasma sourcing, testing, process validation, and batch review.

7. Plasma Master File: Documentation Supporting Plasma Quality

The proposal expressly refers to a Plasma Master File (“PMF”) for documentation and arrangements concerning plasma starting materials, in accordance with applicable legislation. It also links starting-material specifications and release considerations to the relevant marketing authorisation documentation, including the PMF where required.

A PMF provides an organised basis for assessing information about the plasma used in manufacturing. Businesses should review the consistency of their plasma-source information, collection and testing records, supplier arrangements, and supporting quality documentation.

The draft’s references should not be expanded into a claim that it establishes a complete standalone PMF approval procedure or a universal submission requirement for every participant. The applicable documentation requirements must be assessed against the relevant facility, product, and registration arrangements.

Nor should PMF be described as an entirely new concept in Indonesia. BPOM’s published product-registration records already refer to PMF variations, including changes involving plasma collection centres in Indonesia. The proposal would make the connection between plasma manufacturing standards and PMF documentation more explicit.

8. Plasma-Pool Samples and Record Retention

Retention samples allow later investigation of quality or safety concerns associated with plasma used in manufacturing. Their usefulness depends on appropriate storage, identification, and a reliable connection to the resulting finished products.

The existing CPOB annex already provides that samples from each plasma pool should be retained under suitable conditions for at least one year after the expiry of the finished product with the longest shelf life. This should not be characterised as a newly introduced retention period.

Businesses should also distinguish sample retention from document retention. A period specified for plasma-pool samples does not automatically determine the retention period for every donor record, traceability record, batch document, or regulatory submission.

A practical retention review should identify each category of material or record, the applicable period, the responsible custodian, and the means of retrieval. Where suppliers or contract manufacturers hold relevant records, the arrangements should preserve access for investigations and regulatory inspections.

9. Human Plasma Derivatives Used in Medical Devices

The consultation draft states that its requirements may also apply to stable human plasma derivatives, such as albumin, immunoglobulins, and clotting factors, used in medical devices, in accordance with applicable legislation.

That qualification matters. The proposal should not be described as automatically subjecting every medical device manufacturer to all obligations applicable to a PODP manufacturer. The assessment depends on the material, its intended function, the manufacturing activity, and the relevant product classification.

Businesses using plasma derivatives in devices should review the provenance and manufacturing controls of those materials, the supporting supplier documentation, and the requirements applicable to the finished device. Procurement and quality agreements should address access to information needed to substantiate the suitability of the plasma-derived component.

10. What Should Plasma Manufacturers and Suppliers Review Now?

Businesses should begin by mapping their existing obligations under the CPOB Regulation, BPOM Regulation 11/2025, and the certification framework relevant to their activities. This establishes the baseline against which the proposed changes can be assessed.

A focused review should then examine supplier qualification, written quality agreements, donation-to-batch traceability, communication of post-donation information, inventory controls, viral safety procedures, and access to supporting documentation. These are practical areas in which incomplete responsibilities or disconnected records can create compliance difficulties.

The wording of individual provisions also matters. CPOB standards distinguish between mandatory language and provisions expressed as “should.” A legal assessment should preserve that distinction and consider the framework’s treatment of justified alternatives, rather than converting every technical recommendation into an absolute requirement.

Finally, implementation planning should follow the text ultimately adopted by BPOM, including its commencement and any transitional arrangements. The consultation deadline of 28 August 2026 has passed; it should not be presented as a current opportunity to submit comments.

Conclusion

Indonesia’s proposed CPOB amendment would provide a more specific framework for plasma-derived medicinal products, with attention to facility coverage, contract fractionation, supplier responsibilities, risk-based inventory controls, and plasma documentation.

The proposal builds on existing safeguards. Traceability, look-back procedures, controls against cross-contamination, and plasma-pool sample retention already form part of the current CPOB framework. For manufacturers and suppliers, the priority is to identify the actual changes, maintain compliance with existing requirements, and prepare for the final rules through documented quality controls and clear responsibilities across the supply chain.

This article provides general information on Indonesia’s CPOB framework and the consultation proposal for plasma-derived medicinal products. Please contact us to discuss the implications for your manufacturing, sourcing, or contract fractionation arrangements.

Disclaimer: Here